Sustained effects of neonatal systemic lipopolysaccharide on IL-1β and Nrf2 in adult rat substantia nigra are partly normalized by a spirulina -enriched diet

NeuroImmunoModulation

Volumn 23, Issue 4, 2017, Pages 250-259

  Patil, Jaspal ^a   Matte, Ashok ^a   Nissbrandt, Hans ^a   Mallard, Carina ^a   Sandberg, Mats ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Antioxidant system; Neuroinflammation; Nrf2; Spirulina

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA GLUTAMYLCYSTEINE LIGASE CATALYTIC SUBUNIT; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1BETA; LIGASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; NFE2L2 PROTEIN, RAT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME PHOSPHORYLATION; GLUTATHIONE METABOLISM; IN VITRO STUDY; IN VIVO STUDY; INFANT; INFECTION; LACTATION; NONHUMAN; RAT; SPIRULINA; SUBSTANTIA NIGRA; ADMINISTRATION AND DOSAGE; AGE; ANIMAL; DRUG EFFECTS; METABOLISM; NEWBORN; OXIDATIVE STRESS; PHYSIOLOGY; PROTEIN INTAKE; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; DIETARY PROTEINS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SPIRULINA; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 85006237336     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000452714     Document Type: Article

References (41)

1. Martin HL, Teismann P: Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 2009; 23: 3263-3272.
2. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD: Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994; 36: 356-361.
3. Garcia-Garcia A, Zavala-Flores L, Rodriguez-Rocha H, Franco R: Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease. Antioxid Redox Signal 2012; 17: 1764-1784.
4. Krabbe KS, Pedersen M, Bruunsgaard H: Inflammatory mediators in the elderly. Exp Gerontol 2004; 39: 687-699.
5. Liu RM: Down-regulation of gamma-glutamylcysteine synthetase regulatory subunit gene expression in rat brain tissue during aging. J Neurosci Res 2002; 68: 344-351.
6. Cai Z, Fan LW, Kaizaki A, Tien LT, Ma T, Pang Y, Lin S, Lin RC, Simpson KL: Neonatal systemic exposure to lipopolysaccharide enhances susceptibility of nigrostriatal dopaminergic neurons to rotenone neurotoxicity in later life. Dev Neurosci 2013; 35: 155-171.
7. Ling Z, Chang QA, Tong CW, Leurgans SE, Lipton JW, Carvey PM: Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally. Exp Neurol 2004; 190: 373-383.
8. Pang Y, Tien LT, Zhu H, Shen J, Wright CF, Jones TK, Mamoon SA, Bhatt AJ, Cai Z, Fan LW: Interleukin-1 receptor antagonist reduces neonatal lipopolysaccharide-induced longlasting neurobehavioral deficits and dopaminergic neuronal injury in adult rats. Int J Mol Sci 2015; 16: 8635-8654.
9. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A: Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 2010; 58: 588-598.
10. Burton NC, Kensler TW, Guilarte TR: In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology 2006; 27: 1094-1100.
11. Clark J, Simon DK: Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2009; 11: 509-528.
12. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grunblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wullner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR: PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010; 2: 52ra73.
13. Correa F, Ljunggren E, Patil J, Wang X, Hagberg H, Mallard C, Sandberg M: Time-dependent effects of systemic lipopolysaccharide injection on regulators of antioxidant defence Nrf2 and PGC-1alpha in the neonatal rat brain. Neuroimmunomodulation 2013; 20: 185-193.
14. Correa F, Ljunggren E, Mallard C, Nilsson M, Weber SG, Sandberg M: The Nrf2-inducible antioxidant defense in astrocytes can be both up-and down-regulated by activated microglia: involvement of p38 MAPK. Glia 2011; 59: 785-799.
15. Correa F, Mallard C, Nilsson M, Sandberg M: Activated microglia decrease histone acetylation and Nrf2-inducible anti-oxidant defence in astrocytes: restoring effects of inhibitors of HDACs, p38 MAPK and GSK3β. Neurobiol Dis 2011; 44: 142-151.
16. Miranda MS, Cintra RG, Barros SB, Mancini Filho J: Antioxidant activity of the microalga Spirulina maxima . Braz J Med Biol Res 1998; 31: 1075-1079.
17. Careri M, Furlattini L, Mangia A, Musc M, Anklam E, Theobald A, von Holst C: Supercritical fluid extraction for liquid chromatographic determination of carotenoids in Spirulina pacifica algae: a chemometric approach. J Chromatogr A 2001; 912: 61-71.
18. Reddy CM, Bhat VB, Kiranmai G, Reddy MN, Reddanna P, Madyastha KM: Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis . Biochem Biophys Res Commun 2000; 277: 599-603.
19. Patil J, Matte A, Mallard C, Sandberg M: Spirulina diet to lactating mothers protects the antioxidant system and reduces inflammation in post-natal brain after systemic inflammation. Nutr Neurosci 2016, E-pub ahead of print.
20. Piantadosi CA, Withers CM, Bartz RR, Mac-Garvey NC, Fu P, Sweeney TE, Welty-Wolf KE, Suliman HB: Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression. J Biol Chem 2011; 286: 16374-16385.
21. Sakata H, Niizuma K, Yoshioka H, Kim GS, Jung JE, Katsu M, Narasimhan P, Maier CM, Nishiyama Y, Chan PH: Minocycline-preconditioned neural stem cells enhance neuroprotection after ischemic stroke in rats. J Neurosci 2012; 32: 3462-3473.
22. Zhu Y, Carvey PM, Ling Z: Altered glutathione homeostasis in animals prenatally exposed to lipopolysaccharide. Neurochem Int 2007; 50: 671-680.
23. Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rabano A, Kirik D, Cuadrado A: α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in earlystage Parkinson's disease. Hum Mol Genet 2012; 21: 3173-3192.
24. Tsou YH, Shih CT, Ching CH, Huang JY, Jen CJ, Yu L, Kuo YM, Wu FS, Chuang JI: Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal dopaminergic neurons from MPP+ toxicity. Exp Neurol 2015; 263: 50-62.
25. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL: Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007; 66: 75-85.
26. von Otter M, Landgren S, Nilsson S, Celojevic D, Bergstrom P, Hakansson A, Nissbrandt H, Drozdzik M, Bialecka M, Kurzawski M, Blennow K, Nilsson M, Hammarsten O, Zetterberg H: Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med Genet 2010; 11: 36.
27. von Otter M, Landgren S, Nilsson S, Zetterberg M, Celojevic D, Bergstrom P, Minthon L, Bogdanovic N, Andreasen N, Gustafson DR, Skoog I, Wallin A, Tasa G, Blennow K, Nilsson M, Hammarsten O, Zetterberg H: Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech Ageing Dev 2010; 131: 105-110.
28. von Otter M, Bergstrom P, Quattrone A, De Marco EV, Annesi G, Soderkvist P, Wettinger SB, Drozdzik M, Bialecka M, Nissbrandt H, Klein C, Nilsson M, Hammarsten O, Nilsson S, Zetterberg H: Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease-a multicenter study. BMC Med Genet 2014; 15: 131.
29. Todorovic M, Newman JR, Shan J, Bentley S, Wood SA, Silburn PA, Mellick GD: Comprehensive assessment of genetic sequence variants in the antioxidant 'master regulator' Nrf2 in idiopathic Parkinson's disease. PLoS One 2015; 10:e0128030.
30. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Impagnatiello F, Pluchino S, Marchetti B: Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/beta-catenin dysregulation. J Neurosci 2013; 33: 1462-1485.
31. Stromberg I, Gemma C, Vila J, Bickford PC: Blueberry-and Spirulina-enriched diets enhance striatal dopamine recovery and induce a rapid, transient microglia activation after injury of the rat nigrostriatal dopamine system. Exp Neurol 2005; 196: 298-307.
32. Pabon MM, Jernberg JN, Morganti J, Contreras J, Hudson CE, Klein RL, Bickford PC: A Spirulina-enhanced diet provides neuroprotection in an alpha-synuclein model of Parkinson's disease. PLoS One 2012; 7:e45256.
33. Thaakur S, Sravanthi R: Neuroprotective effect of Spirulina in cerebral ischemia-reperfusion injury in rats. J Neural Transm 2010; 117: 1083-1091.
34. Morita K, Itoh M, Nishibori N, Her S, Lee MS: Spirulina non-protein components induce BDNF gene transcription via HO-1 activity in C6 glioma cells. Appl Biochem Biotechnol 2015; 175: 892-901.
35. Cardoso AL, Guedes JR, de Lima MC: Role of microRNAs in the regulation of innate immune cells under neuroinflammatory conditions. Curr Opin Pharmacol 2015; 26: 1-9.
36. Cho SH, Chen JA, Sayed F, Ward ME, Gao F, Nguyen TA, Krabbe G, Sohn PD, Lo I, Minami S, Devidze N, Zhou Y, Coppola G, Gan L: SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. J Neurosci 2015; 35: 807-818.
37. Bilbo SD, Barrientos RM, Eads AS, Northcutt A, Watkins LR, Rudy JW, Maier SF: Early-life infection leads to altered BDNF and IL-1β mRNA expression in rat hippocampus following learning in adulthood. Brain Behav Immun 2008; 22: 451-455.
38. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA: Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol 2000; 166: 127-135.
39. Nagahara AH, Tuszynski MH: Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 2011; 10: 209-219.
40. Credle JJ, George JL, Wills J, Duka V, Shah K, Lee YC, Rodriguez O, Simkins T, Winter M, Moechars D, Steckler T, Goudreau J, Finkelstein DI, Sidhu A: GSK-3β dysregulation contributes to Parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ 2015; 22: 838-851.
41. Xu R, Hu Q, Ma Q, Liu C, Wang G: The protease Omi regulates mitochondrial biogenesis through the GSK3β/PGC-1α pathway. Cell Death Dis 2014; 5:e1373.